Login / Signup

PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis.

Han LiKe SuLu GuoYi JiangKe XuTao GuJiali ChenZhenying WuPan WangXi ZhangYushan YanSiyuan LiXue WuLei HanKun HeLianbin WenBo LiYunwei Han
Published in: Journal of hepatocellular carcinoma (2023)
Antiangiogenic therapy combined with PD-1 inhibitors combined with TACE has significant survival benefits for HCC patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • radiofrequency ablation
  • patient reported outcomes
  • combination therapy
  • smoking cessation
  • liver metastases